Observational studyBreast (Edinburgh, Scotland)2026

Interplay between HER2-Low status, hormone receptor expression, and therapeutic response to cyclin-dependent kinase 4/6 inhibitors as first-line treatment in luminal-like metastatic breast cancer: The CYCLHER study.

Letizia Pontolillo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.